financetom
Business
financetom
/
Business
/
Keurig Dr Pepper raises annual sales forecast on strong beverage demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Keurig Dr Pepper raises annual sales forecast on strong beverage demand
Oct 27, 2025 4:41 AM

(Reuters) -Keurig Dr Pepper ( KDP ) raised its forecast for annual sales on Monday, banking on resilient demand for its energy drinks and carbonated soft beverages in markets including the United States.

Shares of the company, which also beat third-quarter sales estimates, were up about 4% in premarket trading.

U.S. beverage makers are seeing a boost in sales, especially for healthier drinks and low-calorie juices, as consumers opt for wellness-focused options amid the growing popularity of weight-loss drugs and the 'Make America Healthy Again' movement under the Trump administration.

"Strong innovation and in-market execution drove market share gains across key categories, with sales momentum, along with disciplined actions to offset inflationary pressures, contributing to solid earnings and free cash flow growth," CEO Tim Cofer said.

Net sales in Keurig Dr Pepper's ( KDP ) U.S. refreshment beverages segment rose 14.4% in the reported quarter, while U.S. coffee segment saw 1.5% increase.

Price hikes in recent quarters helped the company protect margins from rising tariff-related costs, including on coffee.

Its total prices were up about 4.2%, while volumes grew 6.4%, compared to a year ago.

Activist investor Starboard Value has been building a stake in Keurig Dr Pepper ( KDP ) after the beverage maker in August announced plans to buy European coffee maker JDE Peet's for about $18 billion.

The deal would partly reverse the 2018 merger that created Keurig Dr Pepper ( KDP ), allowing investors to focus on a single segment instead of a diverse product mix.

The company now expects 2025 full-year net sales to grow in a high-single-digit, up from its earlier mid-single-digit range, while keeping its profit forecast unchanged.

Keurig Dr Pepper's ( KDP ) quarterly sales of $4.31 billion beat analysts' estimates of $4.15 billion, according to data compiled by LSEG.

Its adjusted profit of 54 cents per share came in line with Wall Street estimates.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PepGen Names Michelle Mellion as Chief Medical Officer
PepGen Names Michelle Mellion as Chief Medical Officer
Jun 11, 2024
11:59 AM EDT, 06/11/2024 (MT Newswires) -- PepGen ( PEPG ) said Tuesday it appointed Michelle Mellion as chief medical officer, effective immediately. Mellion joined the clinical-stage biotechnology company as senior vice president and head of clinical development, it said. PepGen ( PEPG ) shares were down nearly 3% in recent trading. Price: 17.36, Change: -0.52, Percent Change: -2.91 ...
Mullen Automotive Secures Rebate For Its EV Truck In Massachusetts: Details
Mullen Automotive Secures Rebate For Its EV Truck In Massachusetts: Details
Jun 11, 2024
Mullen Automotive, Inc. ( MULN ) shares are trading lower on Tuesday. The company announced that the Massachusetts Executive Office of Energy and Environmental Affairs Department of Energy Resources had approved its all-electric Class 3 low cab forward truck, the 2024 Mullen THREE, for up to a $15,000 state cash rebate voucher. With the additional $7,500 federal tax credit, the net...
Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment
Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment
Jun 11, 2024
11:56 AM EDT, 06/11/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Tuesday that it has received acceptance of its submission for intranasal foralumab to get Fast Track Designation approval for the treatment of non-active, secondary-progressive multiple sclerosis to the US Food and Drug Administration. Foralumab is a biological drug candidate shown to cause T regulatory cell induction...
Why Barnes & Noble (BNED) Stock Is Volatile
Why Barnes & Noble (BNED) Stock Is Volatile
Jun 11, 2024
Barnes & Noble Education Inc ( BNED ) shares are trading lower by 29.6% to $0.09 during Tuesday’s session after the company announced it has completed equity and refinancing transactions, new leadership changes and a 1-for-100 reverse stock split. The company says the equity and refinancing transactions with Immersion Corporation and existing partners has strengthened its financial position with over...
Copyright 2023-2026 - www.financetom.com All Rights Reserved